{
    "nctId": "NCT06184074",
    "briefTitle": "Effect of Aromatase Inhibitors on Ultrasonographic Measurements and Static and Dynamic Balance Scores in Breast Cancer",
    "officialTitle": "Effect of Aromatase Inhibitors on Lower Extremity Quantitative Ultrasonographic Measurements and Static and Dynamic Balance Scores in Breast Cancer Patients Using Aromatase Inhibitors",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Aromatase Inhibitors, Balanced",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 76,
    "primaryOutcomeMeasure": "Biodex Balance System",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal Woman\n* Between 40-70 ages\n* Stage 1-3 breast cancer\n* Chemotherapy treatment due to breast cancer (Last dosage at least 6 months ago)\n* Using an aromatase inhibitors for at least 1 year for group 1\n* Never using an aromatase inhibitors at all for group 2\n* Volunteers must sign and agree to participate in the study.\n\nExclusion Criteria:\n\n* Stage 4 breast cancer\n* Having active chemotherapy\n* Older age patient (over 70 years old)\n* Using of steroid\n* Presence of diabetes mellitus that lasts longer than 3 years or insulin usage\n* Neuropathic complaints\n* Lack of vitamin B12 and thyroid dysfunction\n* Dn4 (dolour neuropathic 4 question) score of 4 and above\n* History of stroke\n* Presence of polyneuropathy diagnosis\n* Medication due to polyneuropathy diagnosis (gabapentin, pregabalin, duloxetine)\n* Loss of motor function in the lower extremity\n* Use of assistive devices for walking\n* Presence of vestibular disorder\n* Presence of cognitive impairment",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}